We are live on ! Find out more
CTIC

CTI BioPharma Corp. (DE) Common Stock
CTIC

Delisted

CTIC was delisted on the 23rd of June, 2023.

Back to rankings

67 hedge funds and large institutions have $29.7M invested in CTI BioPharma Corp. (DE) Common Stock in 2019 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 20 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more capital invested

Capital invested by funds: $25.6M → $29.7M (+$4.03M)

11% less funds holding

Funds holding: 75 → 67 (-8)

13% less call options, than puts

Call options by funds: $88K | Put options by funds: $101K

40% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 20

57% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 14

Holders
67
Holders Change
-8
Holders Change %
-10.67%
% of All Funds
1.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
12
Reduced
20
Closed
14
Calls
$88K
Puts
$101K
Net Calls
-$13K
Net Calls Change
-$47K

Top Buyers

Rank Fund Capital Flow
1
CC
Caxton Corporation
New Jersey
+$210K
2
Renaissance Technologies
Renaissance Technologies
New York
+$205K
3
PAM
Panagora Asset Management
Massachusetts
+$40.3K
4
State Street
State Street
Massachusetts
+$37.9K
5
CS
Credit Suisse
Switzerland
+$27.7K

Top Sellers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
-$1.82M
2
OM
Opaleye Management
Massachusetts
-$1.03M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$742K
4
Deutsche Bank
Deutsche Bank
Germany
-$266K
5
OAM
Oxford Asset Management
United Kingdom
-$260K

CTIC Hedge Fund Activity: Q1 2019 in Review

67 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q1 2019, worth a combined $29.7M — up 16% from $25.6M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of CTIC and 6 opened new positions — a net loss of 8 holders — while 20 trimmed existing stakes and 12 added.

The largest buyer was Caxton Corporation, adding an estimated $210K. The largest seller was Stonepine Capital Management, cutting an estimated $1.82M.

  • 67 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q1 2019, down from 75 in Q4 2018.
  • Funds reported $29.7M of CTI BioPharma Corp. (DE) Common Stock stock for Q1 2019, up 16% quarter-over-quarter.
  • 6 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q1 2019 and 14 closed out, a net change of -8 holders.
  • The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q1 2019 was Caxton Corporation, an estimated $210K added.
  • The largest CTI BioPharma Corp. (DE) Common Stock seller in Q1 2019 was Stonepine Capital Management, an estimated $1.82M sold.

Based on aggregated 13F filings for Q1 2019.